ALFA Filings
Every announcement, straight from the exchange
Every Aurobindo Pharma earnings call announcement on NSE and BSE, newest first, each with its own page.
Time
4 announcements with these filters
Q1FY27 revenue grew 16% YoY to ₹9,150 Cr. EBITDA margin stood at 21% with PAT of ₹1,032 Cr. Focus remains on complex generics, Lannett integration, and biosimilar monetization.
Aurobindo reported strong Q1FY27 performance with revenue up 16.3% YoY to ₹9,150 Cr and PAT up 25.2% to ₹1,032 Cr, driven by US base business volume gains and European expansion.
Aurobindo delivered record performance in FY26 with revenues at ₹33,653cr and 20.4% EBITDA margins. Strategy focuses on specialty injectables, biosimilars expansion, and backward integration via Pen-G/6-APA projects.
Aurobindo Pharma reported Q4FY26 revenue of ₹8,853 Cr (+5.6% YoY) and PAT of ₹921 Cr (+2.0% YoY). The firm focuses on biosimilars expansion via CuraTeQ and biologics CDMO through TheraNym.